Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

被引:26
作者
Zhu, You-cai [1 ]
Liao, Xing-hui [2 ]
Wang, Wen-xian [3 ]
Xu, Chun-wei [4 ]
Zhuang, Wu [5 ]
Zhong, Li-hua [4 ]
Du, Kai-qi [1 ]
Chen, Yan-ping [4 ]
Chen, Gang [4 ]
Fang, Mei-yu [6 ]
机构
[1] Zhejiang Rongjun Hosp, Dept Chest Dis Diag & Treatment Ctr, Jiaxing, Zhejiang, Peoples R China
[2] Zhejiang Rongjun Hosp, Dept Tumor Mol Lab, Jiaxing, Zhejiang, Peoples R China
[3] Zhejiang Canc Hosp, Dept Chemotherapy, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China
[4] Fujian Med Univ, Canc Hosp, Fujian Prov Canc Hosp, Dept Pathol, Fuzhou, Fujian, Peoples R China
[5] Fujian Med Univ, Canc Hosp, Fujian Prov Canc Hosp, Dept Med Thorac Oncol, Fuzhou, Fujian, Peoples R China
[6] Zhejiang Canc Hosp, Dept Comprehens Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2017年 / 10卷
关键词
lung cancer; ALK; crizotinib; small-cell lung cancer; MECHANISM; CHEMOTHERAPY; INHIBITORS;
D O I
10.2147/OTT.S139718
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is rare. Herein, we report a 49-year-old man diagnosed with adenocarcinoma, who was negative for EGFR and ALK genes as detected by reverse transcription polymerase chain reaction, and was treated with crizotinib. A new biopsy showed a small-cell lung cancer after disease progression. Then, next-generation sequencing (NGS) was carried out and detected a TP53 gene mutation, an ALK rearrangement, and no loss of the retinoblastoma gene (RB). Although a regimen for small-cell lung cancer may be one treatment option, a heterogeneous tumor may exist at the time of diagnosis and manifest during the course of disease.
引用
收藏
页码:3187 / 3192
页数:6
相关论文
共 19 条
[11]   Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib [J].
Miyamoto, Shingo ;
Ikushima, Soichiro ;
Ono, Ryu ;
Awano, Nobuyasu ;
Kondo, Keisuke ;
Furuhata, Yoshiaki ;
Fukumoto, Kento ;
Kumasaka, Toshio .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (02) :170-173
[12]   Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma New Insights in the Era of Molecular Pathology [J].
Norkowski, Emma ;
Ghigna, Maria-Rosa ;
Lacroix, Ludovic ;
Le Chevalier, Thierry ;
Fadel, Elie ;
Dartevelle, Philippe ;
Dorfmuller, Peter ;
de Montpreville, Vincent Thomas .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (10) :1265-1271
[13]   Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin [J].
Oser, Matthew G. ;
Niederst, Matthew J. ;
Sequist, Lecia V. ;
Engelman, Jeffrey A. .
LANCET ONCOLOGY, 2015, 16 (04) :E165-E172
[14]   Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? [J].
Ou, Sai-Hong Ignatius ;
Lee, Thomas K. ;
Young, Lauren ;
Fernandez-Rocha, Maria Y. ;
Pavlick, Dean ;
Schrock, Alexa B. ;
Zhu, Viola W. ;
Milliken, Jeffrey ;
Ali, Siraj M. ;
Gitlitz, Barbara J. .
LUNG CANCER, 2017, 106 :110-114
[15]   Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].
Sequist, Lecia V. ;
Waltman, Belinda A. ;
Dias-Santagata, Dora ;
Digumarthy, Subba ;
Turke, Alexa B. ;
Fidias, Panos ;
Bergethon, Kristin ;
Shaw, Alice T. ;
Gettinger, Scott ;
Cosper, Arjola K. ;
Akhavanfard, Sara ;
Heist, Rebecca S. ;
Temel, Jennifer ;
Christensen, James G. ;
Wain, John C. ;
Lynch, Thomas J. ;
Vernovsky, Kathy ;
Mark, Eugene J. ;
Lanuti, Michael ;
Iafrate, A. John ;
Mino-Kenudson, Mari ;
Engelman, Jeffrey A. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)
[16]   Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].
Shaw, Alice T. ;
Kim, Dong-Wan ;
Nakagawa, Kazuhiko ;
Seto, Takashi ;
Crino, Lucio ;
Ahn, Myung-Ju ;
De Pas, Tommaso ;
Besse, Benjamin ;
Solomon, Benjamin J. ;
Blackhall, Fiona ;
Wu, Yi-Long ;
Thomas, Michael ;
O'Byrne, Kenneth J. ;
Moro-Sibilot, Denis ;
Camidge, D. Ross ;
Mok, Tony ;
Hirsh, Vera ;
Riely, Gregory J. ;
Iyer, Shrividya ;
Tassell, Vanessa ;
Polli, Anna ;
Wilner, Keith D. ;
Jaenne, Pasi A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394
[17]  
Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]
[18]   Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib [J].
Takegawa, N. ;
Hayashi, H. ;
Iizuka, N. ;
Takahama, T. ;
Ueda, H. ;
Tanaka, K. ;
Takeda, M. ;
Nakagawa, K. .
ANNALS OF ONCOLOGY, 2016, 27 (05) :953-955
[19]   Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers [J].
Yu, Helena A. ;
Arcila, Maria E. ;
Rekhtman, Natasha ;
Sima, Camelia S. ;
Zakowski, Maureen F. ;
Pao, William ;
Kris, Mark G. ;
Miller, Vincent A. ;
Ladanyi, Marc ;
Riely, Gregory J. .
CLINICAL CANCER RESEARCH, 2013, 19 (08) :2240-2247